MAESTRO-NAFLD-OLE Phase 3 Trial Completion for Resmetirom
Apr 1, 2026, 4:00:00 AM — trial completion
Summary
Madrigal Pharmaceuticals is expected to complete its Phase 3 MAESTRO-NAFLD-OLE clinical trial of Resmetirom (MGL-3196) in non-alcoholic fatty liver disease (NAFLD) by April 1, 2026. The open-label extension study is designed to evaluate the long-term safety and biomarker effects of Resmetirom, an oral thyroid hormone receptor-β agonist. The trial is recruiting approximately 1,000 participants. Resmetirom is being developed as a potential first-in-class therapy for NAFLD and non-alcoholic steatohepatitis (NASH).
Company
MADRIGAL PHARMACEUTICALS INC (MDGL)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.madrigalpharma.comSimilar Events
MAESTRO-NASH-OUTCOMES Phase 3 Trial Completion Expected
Madrigal Pharmaceuticals is conducting the MAESTRO-NASH-OUTCOMES Phase 3 trial to evaluate resmetirom in patients with well-compensated NASH cirrhosis. The randomized, placebo-controlled study aims to assess the effect of resmetirom on clinical outcomes, including liver-related and cardiovascular mortality, liver transplant, and significant hepatic events. The trial is expected to complete by January 1, 2027. Resmetirom is an oral, once-daily thyroid hormone receptor-β agonist being developed for nonalcoholic steatohepatitis (NASH), a progressive liver disease with limited treatment options.
trial completionPhase 3 Study Completion of MGL-3196 (Resmetirom) in NASH and Fibrosis
Madrigal Pharmaceuticals is expected to complete its Phase 3 clinical trial of MGL-3196 (Resmetirom) for patients with nonalcoholic steatohepatitis (NASH) and fibrosis by January 1, 2028. The study, involving 1,759 participants, aims to evaluate the efficacy and safety of Resmetirom, a thyroid hormone receptor-beta agonist, in improving liver histology in NASH patients with advanced fibrosis. The trial's results could impact the competitive landscape for NASH therapies, an area with significant unmet medical need.
trial completionPhase 3 Efruxifermin NASH/MASH Trial Completion Expected
Akero Therapeutics is conducting a Phase 3 clinical trial of Efruxifermin (EFX) in patients with non-invasively diagnosed nonalcoholic steatohepatitis (NASH/MASH) and nonalcoholic fatty liver disease (NAFLD/MASLD). The study, enrolling 700 participants, is expected to complete on October 1, 2026. Efruxifermin is an investigational FGF21 analog targeting metabolic liver diseases. The trial's primary objective is to assess safety and tolerability compared to placebo.
trial completionExpected Completion of Efruxifermin Phase 3 Trial in NASH/MASH
Akero Therapeutics is conducting a Phase 3, randomized, double-blind, placebo-controlled trial of efruxifermin (EFX) in 1,650 subjects with non-cirrhotic NASH/MASH and fibrosis stages F2 or F3. The trial is expected to complete on November 1, 2032. Efruxifermin is an investigational FGF21 analog targeting metabolic liver diseases. The study's outcome will inform potential regulatory submissions for EFX in NASH/MASH.
trial completion